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ABSTRACT 
Plexiform neurofibroma (PN) tumors are a hallmark manifestation of neurofibromatosis type 1 
(NF1) that arise in the Schwann cell (SC) lineage. NF1 is a common heritable cancer 
predisposition syndrome caused by germline mutations in the NF1 tumor suppressor, which 
encodes a GTPase activating protein called neurofibromin that negatively regulates Ras proteins. 
Whereas most PN are clinically indolent, a subset progress to atypical neurofibromatous 
neoplasms of uncertain biologic potential (ANNUBP) and/or to malignant peripheral nerve 
sheath tumors (MPNSTs). In small clinical series, loss of 9p21.3, which includes the CDKN2A 
locus, has been associated with the genesis of ANNUBP. Here we show that the Cdkn2a 
alternate reading frame (Arf) serves as a gatekeeper tumor suppressor in mice, that prevents PN 
progression by inducing senescence mediated growth arrest in aberrantly proliferating Nf1-/- PN.  
Conditional ablation of Nf1 and Arf in the neural crest derived SC lineage allows escape from 
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senescence, resulting in tumors which accurately phenocopy human ANNUBP and progress to 
MPNST with high penetrance. This animal model will serve as a platform to study the clonal 
development of ANNUBP and MPNST, and to identify new therapies to treat existing tumors 
and to prevent disease progression. 
 
INTRODUCTION 
Neurofibromatosis type 1 (NF1) is one of the most common heritable cancer predisposition 
syndromes, affecting 1 in 3000 individuals in all populations throughout the world (1).  
Plexiform neurofibromas (PN), which are a hallmark manifestation of NF1, are benign nerve and 
soft tissue tumors that manifest within the nerve fascicles driven by bilallelic loss of NF1/Nf1 in 
the embryonic and early neonatal Schwann lineage (SC) in human tumors and in genetically 
engineered murine models (2, 3). PN have a 15% lifetime incidence of transformation to highly 
aggressive sarcomas called malignant peripheral nerve sheath tumors (MPNST) (4), which are 
the leading cause of mortality in NF1 patients. Current MPNST therapies, including surgery and 
chemoradiotherapy, are both debilitating and largely ineffective. Understanding why some PN 
progress to MPNST while others remain indolent is paramount to developing effective treatment 
strategies for preventing disease progression and for early therapeutic intervention.  
 
Beyond early childhood and adolescence, most PN grow slowly at a median growth rate of 3.7% 
per year (5). Further, some PN stop growing entirely despite persistent Ras activation. We 
hypothesized that PN growth arrest results from activation of a senescence program in response 
to chronic Ras hyperactivation. Subsequent escape from this growth arrest may ultimately drive 
progression of PN towards MPNST. The alternate reading frame of CDKN2A (ARF) encodes a 
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tumor suppressor gene that induces senescence-like cell cycle arrest through the stabilization of 
p53 (6). Intriguingly, a number of other benign, slow growing neoplasms harboring oncogenic 
RAS mutations including nevi and colonic adenomas overexpress CDKN2A/ARF and are 
characterized by a signature of senescence prior to tumor progression (7, 8). 
 
Longitudinal imaging studies of NF1 patients with PN have identified a subset of distinct nodular 
lesions that emerge after childhood within existing PN, grow rapidly relative to the surrounding 
tumor, and are FDG-PET avid (9). Biopsies often reveal atypical neurofibromatous neoplasms of 
uncertain biologic potential (ANNUBP), which share some overlapping histopathological 
features with MPNST and have been implicated as potential MPNST precursors (10). 
Intriguingly, karyotyping and microarray analysis identified chromosome 9p21.3 deletions, 
encoding the entire CDKN2A/B locus, as a solitary and highly recurrent genetic aberration in 
human ANNUBP (94%, n=15/16) that were not present in PN (11). Further, haploinsufficient or 
homozygous loss of CDKN2A (p16INK4A) and its alternative reading frame p14ARF was identified 
in 60-80% of MPNSTs in two recent independent studies (12, 13). 
 
Here we provide genetic evidence that the Arf tumor suppressor restrains the proliferation of Nf1-
/- SCs. Our postulate that this phenomenon is due to the activation of a senescence program, 
invoked by Ras hyperactivation, was supported by a broad signature of senescence in both 
murine and human PN.  Further, we show that mice harboring conditional ablation of Nf1 and 
Arf in embryonic neural crest develop tumors that are histopathologically indistinguishable from 
human ANNUBP and subsequently progress to MPNST with high penetrance. Whereas germline 
mouse models where p53(14),  p16(15), or p19Arf (16) are lost in addition to Nf1 develop 
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MPNST and other sarcomas in the absence of apparent premalignant changes, the tissue lineage 
specific model outlined here is the first to recapitulate the malignant transformation of pre-
existing PN and ANNBUP precursor lesions.  Thus, this model provides a tractable platform to 
study the clonal development of ANNUBP and MPNSTs and evaluate novel therapeutic 
strategies. 
 
RESULTS 
Nf1-/- SCs undergo senescence induced growth arrest, driven by Ras-
dependent induction of p19Arf expression 
To test the hypothesis that the outgrowth of Nf1-/- SCs is limited by senescence, we genetically 
ablated Nf1 in embryonic SC progenitors. As anticipated, this resulted in loss of neurofibromin 
protein expression and elevated levels of active Ras-GTP (Figure 1A). This hyperactivation of 
Ras was associated with an initial burst of increased proliferation in Nf1-/- SCs, which was not 
sustained (Figure 1B). Growth arrest was accompanied by robust β-galactosidase expression 
(Figure 1C), an established marker of cellular senescence. Correlating with the increase in β-
galactosidase staining, the expression of the senescence associated transcripts, Cdkn2a(Arf) and 
Cdkn2b were upregulated 5-6 fold in Nf1-/- SCs relative to control wild-type (WT) SCs (Figure 
1D).  Consistent with these data, we observed robust induction of p19Arf, p53, and p16Ink4a 
protein expression in Nf1-/- cells by Western blot (Figure 1E). 
 
Human and murine PN exhibit senescence signature 
We next evaluated human and murine PN for in vivo evidence of a senescence signature. Human 
PN tumors strongly expressed senescence markers. In immunohistochemical (IHC) assays, 
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marked increases in the expression of p16INK4A/p15INK4B (Figure 2A) and the CDKN2A 
alternative reading frame homologue p14ARF (Figure 2B) were observed in human PN as 
compared to control nerve tissues. Similar results were obtained when murine PN were assayed. 
Nf1flox/flox;PostnCre(+) mice harboring conditional biallelic loss of Nf1 in primitive neural crest 
derived progenitor SCs (the tumorigenic cell of origin for PN) driven by Cre-recombinase 
expressed under the control of a 3.9kb segment of the Periostin promoter (PostnCre) (17) 
develop tumors that are histopathologically indistinguishable from human PN.  Peripheral nerve 
tissues and PN arising in Nf1flox/flox;PostnCre(+) mice exhibited significantly increased 
p16Ink4a/p19Arf expression relative to WT controls by IHC staining (Figure 2C, D). Consistent 
with these results, p19Arf expression was also significantly elevated in the trigeminal nerve of 
Nf1flox/flox;PostnCre(+) mice, a cranial nerve that frequently develops plexiform neurofibromas in 
mice and humans (Figure 2E, Supplemental Figure 1). Immunofluorescence (IF) staining for 
S100 to identify neural crest derived progenitors and p16Ink4a/p19Arf to identify senescence 
revealed a high degree of coexpression. Additionally, S100-negative cells were observed as part 
of the tumor microenvironment (Figure 2F). Together with studies of cultures in primary SCs, 
these data indicate that murine and human PN induce known markers of cellular senescence in 
vivo. 
 
These data led us to postulate in PN, indolence and tumor growth arrest may be controlled by 
p19Arf tumor suppressor activity. We therefore bred Nf1 floxed mice with mice harboring a loxP 
site flanking the first coding exon (exon-1β) of the Arf gene, facilitating Cre-mediated excision 
of Arf but leaving the linked Ink4a (Cdkn2a) gene intact (18). Embryonic dorsal root ganglion 
(DRG)/nerve root neurosphere cells (DNSCs) were isolated from the resulting Nf1flox/flox, 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz095/5489753 by R
uth Lilly M
edical Library user on 24 June 2019
Nf1flox/flox;Arfflox/+ and Nf1flox/flox;Arfflox/flox genotypes and infected with Cre recombinase 
expressing adenovirus or empty vector control.  These cells contain the neural crest derived 
tumorigenic cell of origin for PNs (2). Efficient Cre-mediated excision of floxed Nf1 and Arf 
alleles and corresponding loss of protein expression were confirmed by PCR (Supplemental 
Figure 2A) and western blot, respectively (Supplemental Figure 2B). Nf1-Arf double knockout 
(DKO, Nf1-/-; Arf -/-) DNSCs demonstrated increased proliferation compared to WT and Nf1-/- 
DNSCs in a gene dosage dependent fashion (Figure 3A).  Proliferation was confirmed via 
increased cell-cycle entry into S-phase (Figure 3B) of the Nf1-/-;Arf -/- DNSCs.  Unlike Nf1-/- 
DNSCS which exhibited increased senescence, Nf1-/-;Arf +/- and Nf1-/-;Arf -/- DNSCs cultures 
were devoid of senescent cells (Figure 3C, D). However, the percentage of S-phase cells was 
significantly higher in homozygous Arf-mutant DNSCs (Figure 3B). These data indicate that Arf 
inactivation increases the proliferation of Nf1 mutant DNSCs in a dose-dependent manner with 
loss of a single Arf allele overcoming the cellular program invoked by loss of Nf1. 
 
Arf Nf1-/- SC progenitors phenocopy human ANNUBP 
To examine whether Arf loss could directly mediate progression from PN to ANNUBP we 
conditionally ablated Arf in the murine model of Nf1 PN. Following Cre mediated recombination 
and incubation of the mutant mice, microdissection of the lumbosacral nerve plexus revealed a 
generalized thickening of the proximal spinal nerve roots as well as multiple discrete tumors 
arising adjacent to the DRG of Nf1flox/flox, Nf1flox/flox;Arfflox/+ and Nf1flox/flox;Arfflox/flox;PostnCre(+) 
mutant mice (Figure 4A, B).  Arfflox/flox;PostnCre(+) mice revealed normal nerve root 
morphology and architecture (Supplemental Figure 3). Western blot of Nf1/Arf intercrossed 
mice confirmed loss of p19Arf expression (Figure 4C). 
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Histopathological evaluation confirmed the presence of PNs along multiple proximal spinal 
nerve roots in Nf1flox/flox,Nf1flox/flox;Arfflox/+ and Nf1flox/flox;Arfflox/flox;PostnCre(+) mutant mice with 
disrupted nerve architecture, wavy S100+ SCs, increased collagen deposition and mast cell 
infiltration (Table 1 and Supplemental Figure 4). Interestingly, Nf1flox/flox;Arfflox/+ and 
Nf1flox/flox;Arfflox/flox;PostnCre(+) mice also showed outgrowths from peripheral nerves with 
unique histopathological changes not seen in the Nf1flox/flox;PostnCre(+) mice beginning at 
approximately 4 months of life. These lesions met the diagnostic criteria for human ANNUBP 
based on the presence of increased cellularity, cytological atypia (enlarged, hyperchromatic 
nuclei), a fascicular growth pattern and loss of the lattice like CD34+ fibroblastic network seen 
in PN (Table 1, Figure 5, Supplemental Figure 4). Importantly, these lesions also lacked 
mitotic features required for the diagnosis of low grade MPNST. Cervicothoracic spines and 
associated nerve roots were embedded, sectioned and examined systematically at each spinal 
level to identify the presence of tumors meeting diagnostic criteria for PN and ANNUBP (Figure 
6A). The proportion of PN and ANNUBP was similar between Nf1flox/flox;Arfflox/+ and 
Nf1flox/flox;Arfflox/flox;PostnCre(+) mice (Figure 6B) at approximately 6 months of age.  Further, 
while the overall mean proximal nerve root volume was similar amongst the Nf1flox/flox and Nf1-
Arf intercrossed mice, the size of ANNUBP was significantly larger than PN in the same mouse, 
regardless of genotype (Figure 6C). 
 
Spontaneous progression of ANNUBP to MPNST 
A distinguishing feature of  Nf1flox/flox;Arfflox/flox;PostnCre(+) mice was the early development of  
infiltrating and rapidly growing tumors arising from existing PN and ANNUBP lesions (Figure 
7A, B) which met diagnostic criteria for MPNST (Table 1 and Supplemental Figure 4). 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz095/5489753 by R
uth Lilly M
edical Library user on 24 June 2019
Nf1flox/flox;Arf flox/flox;PostnCre(+) mice die of MPNST with 100% penetrance (n =16/16) and a 
mean survival time of 4.8 months. Arf heterozyous Nf1flox/flox;Arf flox/+;PostnCre(+) mice exhibit 
haploinsufficiency with delayed MPNST onset, and a mean survival time of 8.7 months (Figure 
7C). A subset of Nf1flox/flox;PostnCre(+) mice also die from PN nerve compression of vital 
structures. Mice containing a disruption of the Arf allele in Schwann cells did not form tumors 
(Supplemental Figure 3). Collectively, the present results demonstrate causality of sequential 
Nf1 and Arf loss in the progression of PN to ANNUBP and MPNST.  In addition, 
immunofluorescence and immunohistochemical stains against p16Ink4a/p19Arf and pRb confirm 
loss of the senescence signature in vivo with progression of PN to ANNUBP and MPNST 
(Supplemental Figure 5). 
 
DISCUSSION 
Mammalian cells have developed intricate mechanisms to prevent pathological stimuli resulting 
in cells undergoing tumorigenesis and transformation.  When constitutively active stimuli are 
present, such as chronic oncogenic signaling, tumor suppressor networks are engaged that 
antagonized aberrant proliferation by mechanisms that include the induction of cellular 
senescence. The expression of oncogenic Ras induces senescence-like growth arrest in primary 
cells and is regarded a major mechanism to prevent the proliferation of incipient cancer cells 
(19). Colonic serated adenomas initiated oncogenic KrasG12D, overexpress p16INK4A and undergo 
senescence (8). Their progression to malignant adenocarcinomas is linked to Ink4/Arf ablation.  
Similarly, benign melanocytic human nevi, harboring BRAFV600E mutations, have been shown to 
over-express p16INK4A, and acquire CDKN2A mutations upon progression to malignant 
melanoma (20). Previously, Courtois-Cox et al. reported that loss of NF1 induced a senescence 
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in human fibroblasts through up-regulation of p16 (21). Here we show that loss of Nf1 leads to 
hyperactive Ras and increased senescence in primary Schwann cells consistent with these other 
disease models. 
 
Human genetic data from small case series in neurofibromas have led to speculation whether 
haploinsufficient or nullizygous loss of CDKN2A/B is necessary and/or sufficient to promote 
ANNUBP and subsequent progression to MPNST.  One series used microarray to implicate 
chromosome 9p21.3 band deletions as the predominating genetic driver of ANNUBP (11).  A 
second study, consisting of PN and a single ANNUBP suggested that heterozygous loss of 
CDKN2A was sufficient to generate cytologic atypia, but nullizygous loss was required for the 
formation of ANNUBP (22). A confounding feature of both studies was the presence of 
additional gene mutations including known tumor suppressors. The power of genetically 
engineered mouse models allowed us to focus specifically on Arf in the context of Nf1 mediated 
PN formation.  Our experimental findings indicate that inactivating a single allele of Arf in Nf1 
deficient SCs is sufficient to promote the genesis of ANNUBP and MPNST. These findings 
suggest that loss of heterozygosity (LOH) of Arf is not required for the development of 
ANNUBP or malignant transformation. Additional analysis will be required to better understand 
the detailed dynamics of the initiating events. 
 
Developing effective strategies to treat orphan cancers with limited numbers of patients remains 
a clinical challenge. Genetically engineered mouse (GEM) models have demonstrated their 
utility to provide mechanistic insights into the biology of these tumors, thereby serving as a 
catalyst for drug discovery. In particular, genetic and pharmacologic studies in NF1-associated 
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GEM models have predicted patient responses and provided insights into future trials with high 
fidelity (23-26). The studies outlined here thus provide a potential opportunity for treatment and 
prevention of ANNUBP and MPNSTs.  It remains to be determined whether the majority of 
ANNUBP will respond to MEK and other single agent RTK inhibitors that have shown some 
efficacy in treating PN (27, 28). Further, the observation that human ANNUBP and many 
MPNST are Ink4/Arf deficient but p53 competent, provides a unique window of therapeutic 
opportunity for drugs such as MDM2 and/or CDK4/6 inhibitors as potential avenues of 
treatment. 
 
MATERIALS AND METHODS 
Experimental animals and genotyping 
The genetically engineered Nf1 floxed, Arf floxed and PostnCre mice were utilized for in vivo 
studies, with genotypes confirmed by polymerase chain reaction (PCR) as described. The 
WT,Nf1 floxed, and recombination bands were detected using the following primers: P1: 5’-
AATGTGAAATTGGTGTCGA GTAAGGTAACCAC 3’, P2: 5’- 
TTAAGAGCATCTGCTGCTCTTAGAGGGAA 3’, P3: 5’- TCAG 
ACTGATTGTTGTACCTGATGGTTGTACC 3’. The Arf floxed band was detected using 
forward primer: 5’- ACTGCAGCCAGACCACTAGG 3’ and reverse primer: 5’-
AGCTCGGAGATTG AGAAAGC 3’. PostnCre was detected using forward primer: 5’-
ATGTTTAGCTGGCCCAAATG-3’ and reverse primer: 5’-CGACCACTACCAGCAGAACA-
3’. Animal care and experiments were conducted according to the guidelines established by the 
Indiana University Animal Care and Use Committee (IACUC). 
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Nerve tree microdissection and measurement of tumor volume 
Immediately postmortem, fresh blood and select tissues were harvested and mice were perfused 
and fixed in 10% neutral buffered formalin. The bodies were decalcified in a 50:50 solution of 
10% formic acid and 10% neutral buffered formalin solution. The proximal spinal nerve roots 
from the lumbosacral spine were dissected microscopically. The volume of proximal peripheral 
nerves was determined using calipers to measure the length and width of dissected tumors (or 
equivalent region in absence of tumor) in maximal dimension. Volume was then approximated 
using the formula for the volume of a spheroid = 0.52 × (width)2 × length. 
 
Histopathology 
Cervical and thoracic spines with associated DRG and proximal spinal nerve roots were excised 
from euthanized animals, fixed with 10% formalin, decalcified, dehydrated with graded alcohols, 
cleared with xylenes, infiltrated with molten paraffin, and embedded in paraffin blocks. Five 
micron thick sections were cut on a Leica rotary microtome, and stained with hematoxylin and 
eosin (H&E). Mice were also carefully examined for evidence of gross tumors which were 
dissected and excised, formalin fixed, processed, and paraffin-embedded for histopathological 
analysis. The liver and lungs were also harvested to evaluate for evidence of metastatic disease. 
Plexiform neurofibroma (PN), atypical neurofibromas of uncertain biological potential 
(ANNUBP) and malignant peripheral nerve sheath tumors (MPNST) were identified according 
to criteria adopted from a recent consensus overview by Miettinen et al. (10) and are outlined in 
Table 1. 
 
Immunohistochemistry 
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Paraffin sections were deparaffinized, hydrated and transferred to 0.1 M citrate buffer (pH 6.0) 
for antigen retrieval. Slides were pressure cooked for 3 minutes in citrate buffer, cooled for 1 
hour, then rinsed in distilled water. Sections were quenched with 3% hydrogen peroxide for 10 
minutes, rinsed in distilled water, and blocked in 5% normal goat serum in TBST (TBS buffer + 
0.1% tween 20). Sections were incubated overnight at 4°C in primary antibody diluted in 
blocking buffer; S100 (z0311, 1:400 dilution, Dako), CD34 (ab81289, 1:2500 dilution, Abcam), 
H3K27me (CST9733, 1:200 dilution, Cell Signaling Technology), p16Ink4a/p19Arf (ab54210, 
1:500 dilution, Abcam), p15INK4B/p16INK4A (sc377412, 1:250 dilution, Santa Cruz 
Biotechnology) and p14ARF (CST2407, 1:50 dilution, Cell Signaling Technology). Sections were 
then incubated in appropriate biotinylated secondary antibodies for 1 hour at room temperature; 
goat anti-rabbit (B8895, 1:800, Sigma). Vectastain Elite ABC reagent was applied for 30 minutes 
at room temperature. Color development with Vectastain DAB was observed under the 
microscope and the reaction was terminated by rinsing in distilled water. Sections were 
counterstained with modified Mayer’s Hematoxylin (Vector), dehydrated, cleared and 
coverslipped. When anti-mouse primary antibody was used, Rodent Block M (BioCare Medical 
Mouse-on-Mouse HRP Polymer kit, MM510) was applied for 30 minutes at room temperature 
instead of blocking buffer for 1 hour. Additionally, Mouse-on-mouse HRP polymer was applied 
for 15 minutes at room temperature instead of the secondary antibody and ABC reagent. 
Statistical comparisons between control and tumor samples were conducted using Student’s t 
test. Whole slide images were acquired on Aperio ScanScope CS and QImaging Retiga 2000R 
camera on a Nikon Eclipse 80i microscope. 
 
Immunofluorescence 
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Paraffin sections were deparaffinized, hydrated and transferred to 0.1 M citrate buffer (pH 6.0) 
for antigen retrieval. Slides were pressure cooked for 3 minutes in citrate buffer, cooled for 1 
hour, then rinsed in distilled water. Sections were quenched with 3% hydrogen peroxide for 10 
minutes, rinsed in distilled water, and blocked in Rodent Block M (BioCare Medical Mouse-on-
Mouse HRP Polymer kit, MM510) for 30 min. Sections were incubated at 4°C overnight in 
primary antibodies diluted in blocking buffer (5% normal goat serum in TBST); S100 (z0311, 
1:400 dilution, Dako) and p16Ink4a/p19Arf (ab54210, 1:400, Abcam). Sections were then 
incubated in appropriate fluorophore-conjugated secondary antibodies for 1 hour at room 
temperature; goat anti-rabbit 488 (A11034; 1:1000, Invitrogen), goat anti-mouse 568 (A11031, 
1:1000, Invitrogen). Slides were then rinsed and stained with Hoechst 33342 (1:5000, Molecular 
Probes) for 5 minutes at room temperature. Autofluorescence was quenched with Vector 
TrueVIEW. Slides were coverslipped and imaged on the QImaging Retiga 2000R camera on a 
Nikon Eclipse 80i microscope, using an X-Cite 120 fluorescence lamp. Merged images were 
processed using NIH Image J software. 
 
DNSC isolation and culture 
Mouse embryos were removed from pregnant female mice at E13.5 following euthanasia. The 
dorsal root ganglia (DRG) and spinal nerve roots were microdissected under a stereomicroscope. 
DRG and/or nerve root neurosphere culture was performed in serum-free DMEM/F12 media 
containing penicillin/streptomycin (0.1%); fungizone (40 mg/mL); B27 (without vitamin A), 
epidermal growth factor (20 ng/mL), and basic fibroblast growth factor (40 ng/mL; Sigma). The 
sphere cells were fed every 3–4 days and passaged upon reaching confluence. Retaining one-
third of the conditioned medium with fresh medium changes. 
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Schwann cell differentiation from DNSCs 
25,000 DNSCs were seeded on fibronectin coated 12 well plates and cultured in DMEM/F12 
media supplemented with 10% FBS and nerve growth factor (NGF) 200 ng/mL for 6 days.  
 
Proliferation assays 
DNSCs were seeded on fibronectin coated 12 well plates at a density of 50,000 cells per well and 
cultured in serum-free DMEM/F12 media containing penicillin/streptomycin (0.1%); fungizone 
(40 mg/mL); B27 (without vitamin A), epidermal growth factor (20 ng/mL), and basic fibroblast 
growth factor (40 ng/mL; Sigma). Viable cells as determined by trypan blue dye exclusion, were 
counted manually on a glass hemocytometer. 
 
Quantitative RT-PCR 
mRNAs were isolated from primary Schwann cells cultured from 
WTand Nf1flox/flox;PostnCre mice using PureLink RNA Micro Kit (Cat#15596026, 
Thermofisher). mRNA was reverse-transcribed to cDNA using High-Capacity cDNA Reverse 
Transcription Kit with RNase Inhibitor Cat#4374966, Thermofisher). Primers were obtained 
from Invitrogen for quantitative RT-PCR (qRT-PCR) using SYBER-green(Cat#4385612, 
Thermofisher). The sequence of forward and reverse primers utilized for qRT-PCR was as 
follows: Cdkn2a (variant 1(Arf)) forward primer  5′- CATGTTGTTGAGGCTAGAGAGG-3′;  
Cdkn2a reverse primer:  5′-TGAGCAGAAGAGCTGCTACG-3′; Cdkn2b forward primer:  5′- 
CCCTGCCACCCTTACCAGA -3′; Cdkn2b reverse primer: 5’- 
GCAGATACCTCGCAATGTCAC- 3’. Gapdh forward primer 5’- 
TGATGACATCAAGAAGGTGGTGAAG-3’; Gapdh reverse primer 5’- 
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TCCTTGGAGGCCATGTAGGCCAT-3’. Triplicate reactions were performed on an Applied 
Biosystems 7500 Real-Time PCR instrument. Relative gene expression was normalized to 
endogenous Gapdh. The fold change in Cdkn2a and Cdkn2b in Nf1-/- Schwann cells relative to 
WT was determined using the ΔΔCT method. 
 
Senescence 
Cellular senescence was assessed by β-galatosidase utilizing a Senescence Cells Histochemial 
Staining Kit (CS0030, Sigma). Briefly, growth medium was aspirated from adherent cells in 
culture. Cells were washed twice and fixed for 8 minutes at room temperature. Cells were then 
incubated with β-galactosidase (β-gal) staining mixture at 37°C without CO2 for 4 hours or until 
blue staining was apparent. β-gal stained cells and total cells were counted on photomicrographs 
acquired at high power. The percentage of senescence cells expressing β-gal was determined. 
 
Ras activity assays 
A non-radioative Ras Activation Assay Kit (#17-218, Millipore) was used to detect and GTP-
bound Ras in DNSC lysates.  DNSCs were cultured to approximately 90% confluence in 10-cm 
dishes. Upon removal of culture media, cells were rinsed 2x with ice cold PBS, followed by the 
addition of ice cold 500 µL MLB containing 10% glycerol, prepared according to the 
manufacturers recommendation. A cell scraper was used to detach cells from plates and lysates 
were transferred to microfuge tubes on ice, followed by sonication for 5 seconds twice at a 
frequency of 12 KHz. Insoluble cellular debris was pelleted by centrifugation at 14,000xg for 5 
minutes at 4°C. The extract (supernatant) was removed, flash frozen, and stored at -80°C for 
future use. Pull down of Ras-GTP was performed using 10 µg of Ras assay reagent (Raf-1 RBD, 
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agarose), which was added to each cell extract and incubated for 45 minutes with gentle agitation 
at 4°C. Agarose beads were pelleted by brief centrifugation (10 sec, 14,000xg, 4°C). The 
supernatant was removed and discarded. Beads were washed 3x with 500 µL MLB, followed by 
resuspension in 40 µL of 2x Laemmli reducing buffer with 2 µL of 1M dithioteritol and boiled 
for 5 minutes to release GTP-bound Ras from the beads. Ras-GTP was detected by western blot, 
incubating with anti-Ras, clone RAS10 (# 05-516, Millipore) diluted in freshly prepared PBST-
MLK overnight with agitation and goat anti-mouse-HRP conjugate (# 12-349, Millipore) as 
directed. 
 
Western blot 
Isolated proteins were fractionated using NuPAGE 4-12% Bis-Tris Gels (Invitrogen 
Cat#NP0322BOX) and electro-transferred to PVDF membranes. Immunoblots were carried out 
using antibodies specific to p19Arf (Cat#05-929, EMD), p16Ink4a/p15Ink4b (Cat#377412, Santa 
Cruz), p53 (Cat#CST-2524, Cell Signaling Technology), neurofibromin (#SC-67, Santa Cruz), 
and Gapdh (#CST-5174, Cell Signaling Technology). After incubation with appropriate HRP 
conjugated secondary antibodies (Anti-rabbit (#NA934V,GE Healthcare), Anti-Rat(#AP-136P, 
EMD), signals were detected using ECL chemoluminescence substrate (ECL Prime, GE 
Healthcare). 
 
Statistical analysis 
Statistical analyses were performed with GraphPad Prism 7.0 software (GraphPad, La Jolla, CA). 
Analysis of variance (ANOVA) and Student’s t-tests with post-hoc correction for multiple 
comparisons were used to evaluate for statistically significant differences between samples as 
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described in detail within the figure legends. Statistical analysis of Kaplan Meier survival curves 
was performed in SAS software using a logrank test with Bonferroni post-hoc adjustment for 
multiple comparisons. 
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Figure 1. Loss of neurofibromin drives Schwann cell senescence 
A. Ras-GTP activity, neurofibromin and Gapdh (loading control) were detected in WT and 
Nf1-/- SC progenitors by western blot. 
B. Proliferation of WT and Nf1-/- SCs was assessed by manual cell counting. n=3 biological 
replicates per genotype at each timepoint. ***p<0.001 WT vs Nf1-/- by two-way 
ANOVA. 
C. Representative photomicrographs of β-galactosidase stained WT and Nf1-/- primary SCs. 
The percentage of β-galactosidase positive staining cells was quantified. n=3 biological 
replicates per genotype. ****p<0.0001 WT vs Nf1-/- by Student’s t-test. 
D. Expression of senescence associated transcripts,Cdkn2a(Arf) and Cdkn2b in WT and Nf1-
/- SCs. N=3 biological replicates per genotype. *p<0.05 WT vs Nf1-/- by Student’s t-test. 
E. Western blot of p19Arf, p53, p16Ink4a, p15Ink4b, and Gapdh (loading control) in WT and 
Nf1-/- SCs. 
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Figure 2. Murine and human plexiform neurofibroma exhibit a senescence signature  
A. Immunohistochemical (IHC) staining for p16INK4A/p15INK4B was performed on human 
plexiform neurofibroma and healthy control nerve tissues. The percentage of p16INK4 
positive staining cells was quantified. n=8 biological replicates for plexiform 
neurofibroma and n=7 biological replicates for control nerve tissue. **p<0.01 plexiform 
neurofibroma vs normal nerve control by Student’s t-test. 
B. IHC for p14ARF in human plexiform neurofibroma and healthy control nerve tissues. The 
percentage of p14ARF positive staining cells was quantified. n=8 biological replicates for 
plexiform neurofibroma and n=4 biological replicates for control nerve tissue. **p<0.01 
plexiform neurofibroma vs normal nerve control by Student’s t-test. 
C. IHC staining of p16Ink4a/p19Arf expression in peripheral nerve tissue from WT and 
plexiform neurofibroma bearing Nf1flox/flox;PostnCre(+) mice. 
D. The percentage of p16Ink4a/p19Arf-positive staining cells was quantified. n=3 biological 
replicates per group. *p<0.05 for WT vs Nf1flox/flox;PostnCre nerve and tumor tissue. No-
statistically significant difference (ns) comparing Nf1flox/flox;PostnCre nerve and tumor 
bearing tissue. 
E. Western blot of p19Arf and Gapdh in the trigeminal nerve tissues of WT and 
Nf1flox/flox;PostnCre(+) mice. Expression was normalized to Gapdh and quantified in 
relative densitometry units (RDU). **p<0.01 WT vs Nf1flox/flox;PostnCre(+) by one-way 
ANOVA followed by Tukey’s multiple comparisons test. n=5 biological replicates per 
genotype as shown on expanded panel in Supplemental Figure 1. 
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F. Immunofluorescence with anti-S100 (GFP), anti-p16Ink4a/p19Arf (RFP), and nuclear 
(DAPI) markers. Representative merged photomicrographs are shown at 20x 
magnification. 
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Figure 3. Genetic ablation of p19Arf allows Nf1-null DNSCs to escape senescence and 
proliferate aberrantly 
A. Proliferation of WT, Nf1-/-, Nf1-/-;Arf +/- and Nf1-/-;Arf -/- DNSCS was assessed by manual 
cell counting at serial timepoints as shown. The fold change in cell number relative to 
input (50,000 cells/well) is shown. 
B. Cell cycle of WT, Nf1-/-, Nf1-/-;Arf +/- and Nf1-/-;Arf -/- DNSCS was assessed by flow 
cytometry. The percentage of cells in G0/G1, S, and G2/M phase are denoted as shown. 
C. Senescence associated β-galactosidase staining in DNSCs as shown in representative 
photomicrographs. 
D. The percentage of SAS-βgal-positive staining cells relative to total cell number per HPF 
was quantified. ****p<0.0001 for Nf1-/- vs WT, Nf1-/-;Arf +/- and Nf1-/-;Arf -/- by one-way 
ANOVA followed by Tukey’s multiple comparison’s test. n=3 biological replicates per 
genotype. 
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Figure 4. Diffuse morphological changes in the lumbosacral nerve plexus of Nf1/Arf mutant 
mice 
A. The lumbosacral spinal cord, DRG and associated proximal spinal nerve roots were 
microdissected from each genotype: WT, Nf1flox/flox, Nf1flox/flox;Arf flox/+, and Nf1flox/flox;Arf 
flox/flox;PostnCre(+) as shown. 
B. Proximal spinal nerve root volume was measured. The number of proximal spinal nerve 
roots evaluated per genotype are as follows: WT (n=28), Nf1flox/flox;PostnCre(+) (n=16), 
Nf1flox/flox;Arf flox/+;PostnCre(+) (n=16), and Nf1flox/flox;Arf flox/flox;PostnCre(+) (n=24). 
*p<0.05 WT vs Nf1flox/flox;PostnCre(+). ***p<0.001 WT vs Nf1flox/flox;Arf 
flox/+;PostnCre(+). ****p<0.0001 WT vs Nf1flox/flox;Arf flox/flox;PostnCre(+). Statistical 
analysis was performed via one-way ANOVA followed by Sidak’s multiple comparison 
test. 
C. Western blot of p19Arf and Gapdh (loading control) in the trigeminal nerve of each 
genotype. 
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Figure 5. Nf1/Arf mutant mice develop tumors that phenocopy human ANNUBP. 
A. Tumor arising in a 60-year old female patient with a diagnosis of NF1 demonstrating 
increased cellularity, cytological atypia (enlarged, hyperchromatic and pleomorphic 
appearing nuclei), fascicular growth pattern and disruption of the lattice like CD34+ 
fibroblastic network meeting diagnostic criteria ANNUBP. 
B. ANNUBP arising in a representative Nf1flox/flox;Arf flox/+;PostnCre(+) mouse 
recapitulating the histopathological features observed in the human specimen shown 
above. 
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Figure 6. Frequency and size of PN and ANNUBP arising from the cervicothoracic spine of 
Nf1/Arf mutant mice. 
A. Coronal whole spinal sections revealing the spinal cord, dorsal root ganlgia (DRG) with 
associated proximal spinal nerve roots demonstrating PN and ANNUBP arising from the 
proximal nerve roots of Nf1flox/flox;PostnCre(+), Nf1flox/flox;Arfflox/+;PostnCre(+) and 
Nf1flox/flox;Arfflox/flox;PostnCre(+) mice. WT mice exhibited normal nerve architecture and 
cellularity. 
B. Stacked bar plot demonstrating the frequency of PN and ANNUBP arising in the cervical 
thoracic spinal nerve roots of Nf1flox/flox, Nf1flox/flox;Arf flox/+ and 
Nf1flox/flox;Arfflox/flox;PostnCre(+) mice. The number of proximal spinal nerve roots 
evaluated per genotype are as follows: WT (n=85), Nf1flox/flox;PostnCre(+) (n=85), 
Nf1flox/flox;Arf flox/+;PostnCre(+) (n=87), and Nf1flox/flox;Arf flox/flox;PostnCre(+) (n=86). 
C. The maximal diameter of WT control nerve roots and those infiltrated with PN and 
ANNUBP lesions were measured on coronal spinal sections and plotted as shown. The 
number of nerve roots and tumors of each histological subtype are as follows: Normal 
nerve (n=33), PN (n=27) and ANNUBP (n=13). Statistical analysis was performed by 
one-way ANOVA followed by Tukey’s multiple comparisons test. *p<0.05 normal nerve 
vs PN. ****p<0.0001 ANNUBP vs normal nerve and PN. 
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Figure 7. Nf1/Arf mutant mice die from tumor progression to MPNST 
A. Nf1flox/flox;Arfflox/flox;PostnCre(+) mouse with multiple, rapidly growing and  infiltrative 
masses. A diagnosis of MPNST was confirmed histopathologically post-mortem. 
B. PN arising from a thoracic nerve root in a representative Nf1flox/flox;Arfflox/flox;PostnCre(+) 
mouse. Progression to ANNUBP is observed with hypercellularity, cellular atypia and a 
fascicular growth pattern. Subsequent transition to MPNST with encasement/ invasion of 
surrounding rib and multiple mitotic figures is seen. 
C. Kaplan Meier survival curve of WT (n=14), Arf flox/flox;PostnCre(+) (n=9) Nf1flox/flox 
(n=17), Nf1flox/flox;Arf flox/+;PostnCre(+)  (n=17) and Nf1flox/flox;Arf flox/flox;PostnCre(+) 
(n=16) mice. Statistical analysis was performed using a logrank test with Bonferroni 
post-hoc adjustment for multiple comparisons. ***p<0.001 
Nf1flox/flox;Arfflox/flox;PostnCre(+) vs WT, Arfflox/flox;PostnCre(+) and 
Nf1flox/flox;PostnCre(+). **p<0.01 Nf1flox/flox;Arfflox/flox;PostnCre(+) vs Nf1flox/flox;Arf 
flox/+;PostnCre(+). 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz095/5489753 by R
uth Lilly M
edical Library user on 24 June 2019
 D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz095/5489753 by R
uth Lilly M
edical Library user on 24 June 2019
Table 1. Histopathological features and diagnostic criteria for NF1-associated peripheral 
nerve sheath tumors. 
Diagnosis Key Diagnostic Features* 
Plexiform Neurofibroma 
(PN) 
Neoplastic proliferation of S100+ Schwann cells with wavy 
nuclear contours, diffusely enlarging and replacing a major nerve 
trunk. Thickened perineural sheath. Microenvironment consisting 
of fibroblasts with myxoid/collagenous matrix and infiltrating 
inflammatory cells (mast cells and other lineages). Well-
developed, lattice like CD34+ fibroblastic network. 
Atypical 
Neurofibromatous 
Neoplasm of Uncertain 
Biologic Potential 
(ANNUBP) 
Schwann cell neoplasm with at least 2 of 4 features:  (1) 
Hypercellularity as defined by nuclear overlap at high 
magnification; (2) Cytologic atypia - enlarged nuclei at least 2-3x 
> normal, hyperchromasia, pleomorphism with irregular 
chromatin distribution, and/or multinucleated and “bizarre” forms; 
(3) Loss of neurofibroma architecture as defined by fascicular 
growth pattern or disruption of  lattice like CD34+ fibroblastic 
network; (4) Rare mitoses with a mitotic index > 1/50 HPF but < 
3/10 HPF. 
Malignant Peripheral 
Nerve Sheath Tumor 
(MPNST) 
Features of ANNUBP with mitotic index of 3-9/10 HPF without 
necrosis (Low Grade MPNST).  MPNST with a mitotic index 
>10/10 HPF or >3/10 HPF with necrosis (High Grade MPNST). 
 *Adapted from Miettinen et al. Human Pathology (2017) 67, 1-10. 
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ABREVIATIONS 
NF1 – neurofibromatosis type 1 
PN – plexiform neurofibroma 
ANNUBP – atypical neurofibromatous neoplasm of uncertain biological potential 
MPNST – malignant peripheral nerve sheath tumor 
PostnCre – PeriostinCre  
Arf – Cdkn2a alternate reading frame 
SC – Schwann cell 
DRG - dorsal root ganglia 
DNSCs - dorsal root ganglion (DRG)/nerve root neurosphere cells  
GEM - genetically engineered mouse 
ANOVA – analysis of variance  
SAS-βgal – senescence associated β-galactosidase  
 
IHC – immunohistochemical 
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